Jentsch-UlrichK., PelzA.F., BraunH., KoenigsmannM., MohrenM., WieackerP., FrankeA.: Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.Haematologica, 89: 15, 2004.
2.
ViniouN.A., VassilakopoulosT.P., GiakoumiX., MantzouranisM., PamgalisG.A.: Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant PH1(+) acute myeloid leukaemia.Eur J Haematol, 72: 58–60, 2004.
3.
ItoK., TominagaK., SuzukiT., JimaiI., BesshoM.: Successful treatment with imatinib mesylate in a case of minor bcr/abl-positive acute myelogenous leukaemia.Int J Hematol, 81: 242–245, 2005.
4.
KusumotoS., MurohashiI., BesshoM., MatsumotoH., ShimazuM.: The importance of WT1 gene expression in the detection of minimal residual disease. A comparison of WT1 AML/MTG8 transcripts.Rinsho Ketsueki, 40: 511–514, 1999.
5.
WeisserM., KernW., RauhutS., SchochC., HiddemannW., HaferlachT., SchnittgerS.: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.Leukemia, 19: 1416–1423, 2005.
6.
HuS., ChenZ., GuW., ChenJ., ZhaoY.: High expression of RbAp46 gene in patients with acute leukemia or chronic myelogenous leukemia in blast crisis.Chin Med J, 118: 1295–1298, 2005.
7.
EnglertC., MaheswaranS., GarvinA.J., KredbergJ., HeberD.A.: Induction of p21 by the Wilms’ tumor suppressor gene WT1.Cancer Res, 57: 1429–1434, 1997.
8.
EllisenL.W., CarlessN., ChengT., ScaddenD.T., HeberD.A.: The Wilms’ tumor suppressor WT1 directs stage specific quiescence and differentiation of human hematopoietic progenitor cells.EMBO J, 20: 1897–1909, 2001.
9.
SvenssonE., ErikssonH., GekasC., OlofssonT., RichterJ., GullbergU.: DANN-binding dependent and independent functions of WT1 protein during human hematopoiesis.Exp Cell Res, 308: 211–221, 2005.
10.
CilloniD., MessaF., GottardiE., FavaM., ArrogaF., DefilippiI., CarturanS., MessaE., MorottiA., GiuglianoE., Rege-CambrinG., AlbertiD., BaccaraniM., SaglioG.: Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after short in vitro incubation.Cancer, 101: 979–988, 2004.
